{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013207","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.759203+00:00","generated_at":"2026-05-30T17:07:03.540071+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Capricor initiates rolling BLA submission to FDA for deramiocel in DMD cardiomyopathy","bullets":["Rolling submission started Oct 9, 2024; plans to complete by end of 2024.","BLA seeks full approval for deramiocel to treat all DMD cardiomyopathy patients.","No approved treatments currently exist for DMD cardiomyopathy.","Application may be eligible for priority review by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013207","json":"https://secwatch.observer/filing/0001558370-24-013207.json","markdown":"https://secwatch.observer/filing/0001558370-24-013207.md","text":"https://secwatch.observer/filing/0001558370-24-013207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/0001558370-24-013207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/capr-20241009x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:07:03.540071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}